Vulvar Cancer - Pipeline Review, H2 2019

December 2019 | 243 pages | ID: VB6129BB5FAEN
Global Markets Direct

Abstracts

Vulvar Cancer - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2019, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 13, 4 and 2 respectively.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Vulvar Cancer - Overview
Vulvar Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vulvar Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vulvar Cancer - Companies Involved in Therapeutics Development
Antiva Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Brooklyn ImmunoTherapeutics LLC
Cutanea Life Sciences Inc
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Invectys SA
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Ono Pharmaceutical Co Ltd
Shanghai Bovax Biotechnology Co Ltd
SQZ Biotechnologies Co
Transgene SA
Turnstone Biologics Inc
Vulvar Cancer - Drug Profiles
Vulvar Cancer - Dormant Projects
Vulvar Cancer - Discontinued Products
Vulvar Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Vulvar Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Vulvar Cancer - Pipeline by Antiva Biosciences Inc, H2 2019
Vulvar Cancer - Pipeline by AstraZeneca Plc, H2 2019
Vulvar Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2019
Vulvar Cancer - Pipeline by Brooklyn ImmunoTherapeutics LLC, H2 2019
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2019
Vulvar Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Vulvar Cancer - Pipeline by Gilead Sciences Inc, H2 2019
Vulvar Cancer - Pipeline by Invectys SA, H2 2019
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2019
Vulvar Cancer - Pipeline by Merck & Co Inc, H2 2019
Vulvar Cancer - Pipeline by Merck KGaA, H2 2019
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Vulvar Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, H2 2019
Vulvar Cancer - Pipeline by SQZ Biotechnologies Co, H2 2019
Vulvar Cancer - Pipeline by Transgene SA, H2 2019
Vulvar Cancer - Pipeline by Turnstone Biologics Inc, H2 2019
Vulvar Cancer - Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vulvar Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019